[1] Houben RMGJ, Dodd PJ. The Global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 2016;13(10):e1002152. http://dx.doi.org/10.1371/journal.pmed.1002152.
[2] Park SY, Han SM, Kim YM, Kim J, Lee S, Yang J, et al. Risk of active tuberculosis development in contacts exposed to infectious tuberculosis in congregate settings in Korea. Sci Rep 2020;10(1):1306. http://dx.doi.org/10.1038/s41598-020-57697-1.
[3] World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization. 2021. https://www.who.int/publications/i/item/9789240037021. [2022-1-17].
[4] Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015;372(22):2127 − 35. http://dx.doi.org/10.1056/NEJMra1405427.
[5] Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet 2014;384(9944):682 − 90. http://dx.doi.org/10.1016/S0140-6736(14)60162-8.
[6] Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med 2017;167(4):248 − 55. http://dx.doi.org/10.7326/M17-0609.
[7] Oxlade O, den Boon S, Menzies D, Falzon D, Lane MY, Kanchar A, et al. TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up. Int J Tuberc Lung Dis 2021;25(10):823 − 31. http://dx.doi.org/10.5588/ijtld.21.0293.